Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: Results from a phase II trial (Gore L et al. J Clin Oncol, March 2018)

J Clin Oncol, March 2018 
Gore L. M et al

Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients (Suttorp M et al. Pediatr Blood Cancer, August 2018)

Pediatr Blood Cancer, August 2018 (epub ahead of print)
Suttorp M et al. 

Temporal trends in the proportion of "cure" in children and young adults diagnosed with chronic myeloid leukaemia in England: a population-based study (Drozdov D et al. Pediatr Blood Cancer, August 2018)

Pediatr Blood Cancer, August 2018 (epub ahead of print)
Drozdov D et al. 

Pharmacology and pharmacokinets of imatinib in pediatric patients (Suttorp M et al. Expert Rev Clin Pharmacol, Nov 2017)

Expert Rev Clin Pharmacol, November 2017 
Suttorp M et al

Dasatinib-induced Hypopigmentation in pediatric patient with chronic myeloid leukemia: A Case Report and review of the literature

Case Report Dermatol Med, July 2018 
Alharbi B et al. 

  1. Prognostic discrimination based on the EUTOS long term survival score within the international registry for chronic myeloid leukemia in children and adolescents (Millot F et al. Haematologica, August 2017)
  2. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
  3. The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy (Samis J et al. Pediatr Blood Cancer, July 2017)
  4. Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia (Ernst T et al. Leukemia, June 2018)